8 MonoGerm: Phase II trial of carboplatin or vinblastine monotherapy prior to radiotherapy for intracranial germinoma, using novel proof-of-principle Bayesian design

Clicks: 15
ID: 326721
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #226 of 286 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 286 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Current European standard-of-care for localised intracranial germinoma is multi-agent chemotherapy (carboPEI: carboplatin/etoposide/ifosfamide) followed by definitive radiotherapy, with excellent survival. MonoGerm is a de-escalation, non-inferiority trial aiming to reduce toxicity. Twelve-week carboplatin AUC10 or vinblastine induction will be compared with carboPEI from SIOP-CNS-GCT-II. A novel trial design is required to answer this question pragmatically/safely. Methods Clinical trials in rare diseases recruit slowly, allowing continuous monitoring of efficacy outcomes. Efficacy-transition-pathways (ETP) are innovative visual tools to aid determination of trial design parameters, and an extension of the dose-transition-pathways concept introduced for dose-finding trials. Results MonoGerm includes two monotherapies; each single arm recruiting six cohorts of three patients, with interim assessment after each recruited cohort and final analysis at 18 patients (total n = 36). Insufficient tumour volume response (<30%) at 6-week safety MRI results in 12-weeks carboPEI. Primary outcome is radiological complete response (CR) by 12-weeks of induction monotherapy. A beta-binomial conjugate analysis will generate posterior probability distributions, combining observed trial data as realisations from a binomial distribution with a minimally informative Beta (1,1) prior. Decision criteria to allow early stopping at interim analyses and go/no-go decisions at final analysis are based on probabilities from these distributions. ETP visually maps out parameters used to assert decisions after each interim assessment as a pyramid decision tree. For each recruited cohort and every CR outcome, estimates of the true CR rate and probabilities with associated decisions are mapped. ETP allows clear communication between statisticians, clinicians, and patient-public-involvement teams, facilitating informed decisions in an efficient/realistic trial design. Conclusion MonoGerm, a Litte Princess Trust-funded novel Bayesian de-escalation trial, uses ETP and continuous monitoring with built-in stopping rules to ensure patient safety in this treatment de-escalation study.
Reference Key
openalex_W7204454521 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Laura Kirton, John Apps, Anna Lawson, Theodoros Arvanitis, Dipayan Mitra, Richard Gagen, Hiten Patel, Andrew Peet, Lorna Fern, Emma Williams, Nicholas Coleman, Thankamma Ajithkumar, Brigitte Bison, Gareth Veal, Daniel Stark, Shivani Bailey, Cinzia Scarpini, Giovanni Morana, James Nicholson, Lucinda Billingham, Matthew Murray
Are you one of these authors? Claim your profile
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag172.064
URL
https://academic.oup.com/neuro-oncology/article-pdf/28/Supplement_1/noag172.064/70805806/noag172.064.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.